Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Digestive System Neoplasms 1

Interventions

repotrectinib 1pralsetinib 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1anlotinib 1alectinib 1Sunitinib 1Lutetium-177 1Lutetium 1E-7386 1Cholecystectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Neoplasms × anlotinib × NET × Clear all
NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡